101 related articles for article (PubMed ID: 19148510)
1. HPV-16E6 can induce multiple site phosphorylation of p53.
Zhang G; Sun L; Li Z; Si L; Song T; Huang C; Zhang W
Oncol Rep; 2009 Feb; 21(2):371-7. PubMed ID: 19148510
[TBL] [Abstract][Full Text] [Related]
2. GFP/HPV-16E6 fusion protein induces apoptosis in MCF-7 and 293T cells using a transient expression system.
Zhang G; Liu Y; Yu L; Sun L
Oncol Rep; 2012 Nov; 28(5):1673-80. PubMed ID: 22922869
[TBL] [Abstract][Full Text] [Related]
3. In GFP with high risk HPV-18E6 fusion protein expressed 293T and MCF-7 cells, the endogenous wild-type p53 could be transiently phosphorylated at multiple sites.
Sun L; Zhang G; Li Z; Song T; Huang C; Si L
J Exp Clin Cancer Res; 2008 Sep; 27(1):35. PubMed ID: 18778462
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.
Hiller T; Poppelreuther S; Stubenrauch F; Iftner T
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1262-7. PubMed ID: 16835321
[TBL] [Abstract][Full Text] [Related]
5. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
Hampson L; Kitchener HC; Hampson IN
Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826
[TBL] [Abstract][Full Text] [Related]
6. The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein, p53.
Etscheid BG; Foster SA; Galloway DA
Virology; 1994 Dec; 205(2):583-5. PubMed ID: 7975261
[TBL] [Abstract][Full Text] [Related]
7. Cellular distribution of tumour suppressor protein p53 and high-risk human papillomavirus (HPV)-18 E6 fusion protein in wild-type p53 cell lines.
Sun L; Zhang G; Li Z; Lei T; Huang C; Song T; Si L
J Int Med Res; 2008; 36(5):1015-21. PubMed ID: 18831896
[TBL] [Abstract][Full Text] [Related]
8. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.
Giovane C; Trave G; Briones A; Lutz Y; Wasylyk B; Weiss E
J Mol Recognit; 1999; 12(2):141-52. PubMed ID: 10398405
[TBL] [Abstract][Full Text] [Related]
9. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
[TBL] [Abstract][Full Text] [Related]
10. HPV-16 E6 oncoprotein induces mutations via p53-dependent and -independent pathways.
Kim HJ; Guo W; Park NH
Oncol Rep; 2000; 7(4):707-12. PubMed ID: 10854530
[TBL] [Abstract][Full Text] [Related]
11. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
Rampias T; Sasaki C; Weinberger P; Psyrri A
J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448
[TBL] [Abstract][Full Text] [Related]
12. Signals that dictate nuclear localization of human papillomavirus type 16 oncoprotein E6 in living cells.
Tao M; Kruhlak M; Xia S; Androphy E; Zheng ZM
J Virol; 2003 Dec; 77(24):13232-47. PubMed ID: 14645580
[TBL] [Abstract][Full Text] [Related]
13. Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis.
Cheng YW; Wu TC; Chen CY; Chou MC; Ko JL; Lee H
Clin Cancer Res; 2008 Nov; 14(22):7173-9. PubMed ID: 19010833
[TBL] [Abstract][Full Text] [Related]
14. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
15. The location of endogenous wild-type p53 protein in 293T and HEK293 cells expressing low-risk HPV-6E6 fusion protein with GFP.
Sun L; Shen X; Liu Y; Zhang G; Wei J; Zhang H; Zhang E; Ma F
Acta Biochim Biophys Sin (Shanghai); 2010 Mar; 42(3):230-5. PubMed ID: 20213049
[TBL] [Abstract][Full Text] [Related]
16. The high-risk HPV E6 oncoprotein preferentially targets phosphorylated nuclear forms of hDlg.
Narayan N; Subbaiah VK; Banks L
Virology; 2009 Apr; 387(1):1-4. PubMed ID: 19307009
[TBL] [Abstract][Full Text] [Related]
17. p53-independent abrogation of a postmitotic checkpoint contributes to human papillomavirus E6-induced polyploidy.
Liu Y; Heilman SA; Illanes D; Sluder G; Chen JJ
Cancer Res; 2007 Mar; 67(6):2603-10. PubMed ID: 17363579
[TBL] [Abstract][Full Text] [Related]
18. The pro-angiogenic factors stimulated by human papillomavirus type 16 E6 and E7 protein in C33A and human fibroblasts.
Xi L; Wang S; Wang C; Xu Q; Li P; Tian X; Wu P; Wang W; Deng D; Zhou J; Ma D
Oncol Rep; 2009 Jan; 21(1):25-31. PubMed ID: 19082439
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
Hawkins DS; Demers GW; Galloway DA
Cancer Res; 1996 Feb; 56(4):892-8. PubMed ID: 8631030
[TBL] [Abstract][Full Text] [Related]
20. Intracellular scFvs against the viral E6 oncoprotein provoke apoptosis in human papillomavirus-positive cancer cells.
Lagrange M; Boulade-Ladame C; Mailly L; Weiss E; Orfanoudakis G; Deryckere F
Biochem Biophys Res Commun; 2007 Sep; 361(2):487-92. PubMed ID: 17658466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
